Hepion Pharmaceuticals

Shareholders of Hepion Pharmaceuticals elected five directors (Gary Stetz, Vincent LoPriore, Michael Purcell, Sireesh Appajosyula and Chase LoPriore) and ratified Grassi & Co. as independent auditors for the year ending December 31, 2026. They also approved an amendment to the 2023 Omni Equity Incentive Plan increasing the issuable share pool from 200,000 to 8,000,000. In addition, CEO Dr. Kaouthar Lbiati resigned for personal reasons and received a severance payment of $225,000, a prorated cash bonus of $30,625 and six months of COBRA insurance coverage. » Więcej na de.investing.com

Hepion Pharmaceuticals announced that Dr. Kaouthar Lbiati has resigned as chief executive officer and as a member of the board for personal reasons. She received a separation agreement providing a severance payment of $225,000, a prorated cash bonus of $30,625 and reimbursement of COBRA health insurance premiums for six months. The stock has recently posted steep losses (down 88% year-to-date; down 14% last week), and the company has a market capitalization of around $560,000. » Więcej na de.investing.com

Hepion Pharmaceuticals has appointed Dr. Kaouthar Lbiati as Chief Executive Officer effective January 8, 2026. Her annual base salary is $350,000 with a partially deferred component, a performance-based cash bonus expected to be 35% of the base salary, and additional change-of-control bonuses; severance and vesting arrangements for shares and options on termination were contractually agreed. The company states that there are no arrangements with third parties and no familial relationships with other directors or executives. » Więcej na de.investing.com

Hepion Pharmaceuticals has announced the resignation of CFO John Brancaccio, who is leaving the company for personal reasons. The company is facing delisting from NASDAQ and plans to trade its shares on the OTC Markets Group in the future, while strategically shifting its focus from drug development to diagnostics. Kaouthar Lbiati has been appointed interim CFO, and a new licensing agreement with New Day Diagnostics LLC is expected to generate short-term revenue in the EU. » Więcej na de.investing.com